Project Grant R03DE036395
- Federal Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded $433,125 to the University of California, Los Angeles under the Oral Diseases and Disorders Research program (CFDA 93.121) on August 20, 2025, to support a project investigating small molecule inhibitors against human papillomavirus (HPV)-induced oropharyngeal cancers. This R21 pilot project will deliver research services and drug screening capabilities designed to identify therapeutic...
- Federal Project Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded the University of Pittsburgh a $1.9M Project Grant (CFDA 93.121: Oral Diseases and Disorders Research) effective September 19, 2025, through September 18, 2028, to conduct computational and experimental research analyzing high-dimensional genomic datasets from human head and neck squamous cell carcinomas (HNSCC). The project will employ systems biology modeling and novel analytical...
- Federal Grant Award Summary The Ohio State University received a $315,000 Project Grant award from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), effective July 15, 2025, through July 14, 2027. This award supports research focused on developing novel antibody therapeutics to target Human Papillomavirus (HPV) oncoproteins E6 and E7 in HPV-positive head and neck cancer (HNC). The research leverages the...
- Federal Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $219,660 Project Grant to the Regents of the University of Michigan, effective January 1, 2029, under the Oral Diseases and Disorders Research program (CFDA 93.121). This research initiative, titled "Intercepting the Evolution of Pro-Tumoral Myeloid Cells During the Initiation of Oral Cancer," delivers preclinical research services focused on understanding the immunological...
- Federal Grant Award Summary The University of Chicago received a $451,000 Project Grant awarded July 15, 2025, through the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The two-year project (completion date July 14, 2027) supports research to decipher the mechanisms of response to HB-200, a novel human papillomavirus (HPV)-specific viral immunotherapy platform designed to treat HPV-associated oropharyngeal...
- Federal Grant Award Summary Baylor College of Medicine received a $320,000 Project Grant from the National Institute of Dental and Craniofacial Research under the Oral Diseases and Disorders Research program (CFDA 93.121) awarded July 15, 2025, with a completion date of July 14, 2027. The research focuses on understanding the mechanisms of radiotherapy resistance in immunologically cold, Human Papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). The project delivers...
- Federal Project Grant Award Summary The National Cancer Institute awarded $544,250 to the University of Nebraska Medical Center (UNMC) under the Cancer Treatment Research program (CFDA 93.395) for a five-year project running from August 4, 2025 through July 31, 2030. The award supports research investigating the immune drivers of persistent oncogenic human papillomavirus (HPV) infections in people living with HIV (PLWH), with an initial focus on oral HPV persistence as a precursor to...
- Federal Grant Award Summary Innotech Precision Medicine, Inc., a woman-owned small business, received a $1,414,853 Project Grant awarded on August 8, 2025, by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121). The award supports Phase II development of RECOGNIZE-OPSCC, a saliva-based, point-of-care diagnostic test designed to detect oropharyngeal squamous cell carcinoma (OPSCC) through rapid (within 30...
- Federal Project Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded a $1.47 million Project Grant to the University of Texas MD Anderson Cancer Center on March 1, 2026, under the Oral Diseases and Disorders Research program (CFDA 93.121). The five-year award, extending through February 28, 2031, supports research to elucidate subclonal evolution and fitness dynamics in oral carcinogenesis. The project addresses the significant clinical challenge that...
- Federal Grant Award Summary The National Institute of Dental and Craniofacial Research (NIDCR) awarded West Virginia University Research Corporation a $418,000 Project Grant on August 20, 2025, under the Oral Diseases and Disorders Research program (CFDA 93.121) to support research on ferroptosis-related therapeutic targets for head and neck squamous cell carcinoma (HNSCC). The project, which runs through August 19, 2027, focuses on investigating CISD1 (mitoneet), an iron-sulfur...
The University of Arizona received a $284,714 Project Grant from the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), awarded July 8, 2026, with completion targeted for July 7, 2028. This research initiative will deliver genomic analysis and identification of therapeutic targets for human papillomavirus (HPV)-associated oral cancers, specifically oropharyngeal squamous cell carcinoma (OPSCC). The project will employ gene co-expression network analysis methods to characterize long non-coding RNA (lncRNA)-mediated regulatory networks and identify hub lncRNAs that distinguish HPV16-driven cervical cancers from OPSCC, with particular focus on differences between episomal and integrated viral genome states in head and neck tumors. The research deliverables will include comparative analysis of publicly available TCGA (The Cancer Genome Atlas) datasets using weighted gene co-expression network analysis (WGCNA) to identify lncRNA-associated regulatory modules, validation studies in secondary datasets, identification of lncRNAs associated with HPV16 integration status in OPSCC samples, and experimental validation using clinical samples and cell culture models. These outputs are intended to elucidate lncRNA-mediated regulatory mechanisms in HPV-associated cancers and establish a foundation for precision intervention strategies in head and neck cancer treatment.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $284.7k | 7/9/26 |